Centessa Pharmaceuticals (CNTA) Non-Current Debt (2021 - 2026)

Centessa Pharmaceuticals (CNTA) has 6 years of Non-Current Debt data on file, last reported at $110.4 million in Q1 2026.

• Quarterly Non-Current Debt rose 1.09% year-over-year to $110.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.4 million (up 1.09% YoY) and the FY2025 annual result came in at $110.1 million, up 1.06% from the prior year.
• Non-Current Debt was little changed at $110.4 million in Q1 2026 per CNTA's latest filing, from $110.1 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $110.4 million in Q1 2026 and bottomed at $67.4 million in Q2 2022.
• The 5-year median for Non-Current Debt is $75.7 million (2023), against an average of $86.0 million.
• The widest annual swing landed in 2022, when Non-Current Debt fell 7.79%; it then jumped 45.07% in 2025.
• Tracing CNTA's Non-Current Debt over 5 years: stood at $69.8 million in 2022, then increased by 8.45% to $75.7 million in 2023, then surged by 43.91% to $108.9 million in 2024, then increased by 1.06% to $110.1 million in 2025, then climbed by 0.31% to $110.4 million in 2026.
• Per Business Quant, the three latest CNTA Non-Current Debt figures stand at $110.4 million (Q1 2026), $110.1 million (Q4 2025), and $109.8 million (Q3 2025).

Peer Comparison